PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/QKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this inExchange from PeerView, a multidisciplinary team of experts from oncology, endocrinology, and pathology discuss the advantages of a team-based approach to NTRK fusion testing and TRK inhibition in thyroid cancer. In this 30-minute learning opportunity, you'll hear how endocrinologists can lead the interprofessional charge to enhance outcomes by optimizing NTRK fusion testing and TRK-targeted therapy. This presentation covers the rationale, science, and evidence, and presents actionable strategies for putting the data into practice for patients with fusion-positive thyroid cancer. Upon completion of this activity, participants should be better able to: Explain the rationale for testing for NTRK fusions in patients with thyroid cancer, including their role in disease development and progression and impact on prognosis and treatment algorithms; Cite current efficacy and safety evidence on TRK-targeted therapies in patients with NTRK fusion–positive thyroid cancers; Implement practical strategies to ensure patients with thyroid cancer receive timely and appropriate NTRK fusion testing in order to inform optimal therapeutic decision-making; and Apply best practices for collaboration and coordination of care with multidisciplinary colleagues for patients with NTRK fusion–positive thyroid cancer, including appropriate integration of TRK-targeted therapies into treatment plans and recognition/management of treatment-related adverse events.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.

Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don't miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

Go online to PeerView.com/JFN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimized use of asparaginase is a cornerstone of successful administration of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) and has implications for patient outcomes across populations—are you prepared for the emergence of novel asparaginase formulations and the use of strategies that can help avoid treatment discontinuation? This MasterClass & Case Forum video presents an opportunity to understand and surmount the challenges associated with delivering effective ALL care with the asparaginase component of modern therapy. In this activity, an expert panel addresses topics ranging from current guidance on first- and second-line asparaginase options, monitoring and management of barriers such as asparaginase hypersensitivity, and therapeutic planning using available tools to maintain asparaginase exposure. Upon completion of this activity, participants should be better able to: Summarize comprehensive management recommendations for pediatric, AYA, and adult patients with ALL, including chemotherapy and asparaginase protocols, immunotherapy, and tyrosine kinase inhibitors; Cite the clinical impact of E coli asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations; Develop evidence-based treatment plans for asparaginase sequencing with E coli and Erwinia asparaginase, including recombinant formulations; and Manage E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.

Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

Go online to PeerView.com/NTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice. Upon completion of this activity, participants should be better able to: Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence; Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy; and Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers.

Go online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy. Upon completion of this activity, participants should be better able to: Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM); Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM; and Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting.

Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.

Go online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on both disease stage and a variety of patient- and treatment-specific factors. Participate in this PeerView activity for an in-depth examination of how interventional radiologists can collaborate with the HCC management team to offer the best possible care for their patients! Upon completion of this activity, participants should be better able to: Evaluate the current and emerging therapeutic roles of and key clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immune checkpoint inhibitors, and combinations, for patients with intermediate- to advanced-stage HCC; Recommend clinical trials assessing innovative strategies, including tumor treating fields, Y-90 glass and resin microspheres, and combinations of locoregional and systemic therapies, to patients with HCC across the disease spectrum; and In collaboration with multidisciplinary colleagues, develop evidence-based management plans that incorporate novel therapeutic approaches, patient-specific factors such as underlying liver disease severity and biomarker status, and expert recommendations on timely transitions from locoregional to systemic therapy for patients with intermediate- and advanced-stage HCC.

Go online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event held at the 2022 American Society of Clinical Oncology Annual Meeting, our expert panel links the evidence supporting the use of immunotherapy in locally advanced and metastatic BCC with case-based teaching designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards, ultimately illustrating how checkpoint inhibitors can be integrated into the care of patients with BCC. Leverage the power of immunotherapy to improve clinical outcomes for your patients with advanced BCC! Upon completion of this activity, participants should be better able to: Cite the rationale, therapeutic role, and current evidence and guidelines supporting the use of immune checkpoint inhibitors (ICIs) in the management of advanced BCC; Integrate novel immunotherapy options into the management of appropriate patients with advanced BCC in consultation with the wider management team; and Employ proactive, team-based approaches to recognize, mitigate, and manage potential immune-related adverse events in patients receiving ICI therapy for advanced BCC.

Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.

Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.

Go online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. CDK4 and 6 inhibitors and endocrine therapy have significantly improved outcomes in ER+/HER2- advanced breast cancer, and recently, the first CDK4 and 6 inhibitor was approved in combination with endocrine therapy in the adjuvant setting for patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20%. However, pretreated ER+/HER2- breast cancer remains a challenging area with limited treatment options. A number of novel ER-targeting therapies are being investigated in this setting and are showing great promise, including oral selective estrogen receptor degraders (SERDs), selective estrogen receptor modifiers (SERMs), SERD/SERM hybrids, selective estrogen receptor covalent antagonists (SERCAs), and proteolysis-targeting chimeras (PROTACs). This activity, based on a PeerView Live Seminars & Practicum educational web broadcast held in conjunction with the 2022 ASCO Annual Meeting, provides the multidisciplinary breast cancer care team with the latest research and evidence on current and emerging targeted and endocrine therapy options and the implications of these therapeutic advances for practice to ensure that more patients benefit and have improved outcomes. The patient perspective is highlighted as well, and advice for overcoming persistent disparities in breast cancer clinical care are shared. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including CDK4 and 6 inhibitors, SERDs, and SERCAs, and their evolving role in clinical practice; Develop personalized treatment plans for patients with ER+/HER2- breast cancer that take into account recent approvals and safety and efficacy findings from emerging therapies in the context of clinical practice or clinical trials, particularly in areas of high unmet need; and Integrate a team-based, collaborative, and coordinated approach to care, educate patients about new and emerging treatment options for which they may be eligible, and engage patients in shared decision-making to ensure that their unique needs and preferences are taken into account when making treatment decisions.

Go online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more patients achieving cure. The number of available ICIs is expected to grow, as many new agents and combinations are in the final stages of testing, and novel checkpoints such as TIGIT and LAG-3 are showing promise in clinical trials. Consequently, predictive biomarker testing to refine treatment selection is paramount, and there is increasing focus on new surrogate endpoints to assess ICI efficacy, especially in early-stage settings where pathologic complete response, major pathologic response, and disease-free survival are helping to move the field forward faster. However, these exceptional advances are not without challenges. Not all patients with lung cancer benefit from ICIs, while others who could benefit do not have access to these therapies due to persistent disparities in biomarker testing, clinical care, and research. Determining the best immunotherapy option for each individual patient at the right time and in alignment with the particular needs and preferences of each patient is not simple and requires multidisciplinary collaboration and patient-centric shared decision-making. In addition, astute vigilance is required to mitigate potential immune-related adverse events (irAEs) to keep more patients benefiting from these therapies. This activity, based on a PeerView Live Seminars & Practicum educational event held at the 2022 ASCO Annual Meeting, provides guidance for navigating the evidence supporting the use of current and emerging immunotherapies throughout the NSCLC disease continuum and translating evidence to practice with the goal of improving patient outcomes in both advanced/metastatic and early-stage settings. Produced in partnership with LUNGevity Foundation, patient perspectives are also emphasized to improve team-based collaboration, patient engagement, shared decision-making, and health equity in clinical care and research. Upon completion of this activity, participants should be better able to: Describe the latest evidence supporting the use of current and emerging immune checkpoint inhibitors (ICIs) and combinations in locally advanced or metastatic and early-stage non–small cell lung cancer (NSCLC); Select the most appropriate ICI-based treatment for eligible patients with locally advanced/metastatic and early-stage NSCLC, considering the disease presentation, tumor characteristics, biomarker results, patient needs and preferences, current evidence and guidelines, multidisciplinary perspectives, and other relevant factors; Implement multidisciplinary and patient-centric approaches to ensure optimal and equitable use of immunotherapies in the care of all eligible patients with NSCLC; and Apply current guidelines and best practices for monitoring and management of immune-related adverse events (irAEs) in patients with NSCLC who are receiving or have received immunotherapy.

Go online to PeerView.com/HVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What is your sense of the “next steps” with practice-changing immunotherapy options for head and neck cancer (HNC)? Future advances will likely be driven by longer-term evidence in recurrent/metastatic disease, the use of immunotherapy in conjunction with surgery and radiotherapy, the potential of novel combinatorial regimens, and the emergence of newer PD-1–targeting therapies or innovative immune-based treatments. In this “Clinical Consult” activity, based on a live symposium held at the 2022 ASCO Annual Meeting and developed in collaboration with the Head and Neck Cancer Alliance (HNCA), a panel of experts will use case-based conversations to illustrate the present and future of immunotherapy across lines of care in HNC and provide guidance on the next wave of innovation emerging from clinical trials. Upon completion of this activity, participants should be better able to: Summarize updated clinical evidence and guideline recommendations regarding the use of checkpoint inhibitors and other immunotherapy options to treat the spectrum of head and neck cancer; Incorporate checkpoint inhibitors into treatment plans for resectable, locally advanced, and recurrent/metastatic head and neck cancer based on current evidence, guideline recommendations, patient preferences, and availability of clinical trials; and Develop a management plan for immune-related adverse events associated with checkpoint inhibitors used as monotherapy or in conjunction with other modalities.

Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

Go online to PeerView.com/GBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)—a serious complication arising in the aftermath of hematopoietic stem cell transplantation? In addition to life-threatening organ dysfunction in serious cases, VOD presents additional diagnostic and assessment challenges based on its varied onset time and symptomatology. PeerView's Clinical Consults CME video will help you meet these challenges head-on through a series of case-centric lectures illustrating how modern VOD management techniques can improve outcomes in adult and pediatric patients at risk for this post-transplant complication. Throughout, our expert panelists will highlight the modern tools and evidence that can help capture VOD cases, determine the presence of organ dysfunction, and support the initiation of timely supportive care and pharmacologic treatment. Upon completion of this activity, participants should be better able to: Describe risk factors for VOD/SOS, updated diagnostic criteria, and clinical markers of disease severity/multiorgan failure, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including for individuals presenting with or without organ dysfunction, Use modern severity grading models to determine the presence of organ dysfunction in patients with a VOD/SOS diagnosis, Incorporate novel therapies into treatment plans for VOD/SOS, including in the setting of multiorgan dysfunction, based on clinical assessment and current evidence.

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.

Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to reflect the innovative science supporting the use of modern asparaginase compounds in pediatric ALL. Upon completion of this activity, participants should be better able to: Describe the clinical ramifications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Cite efficacy and safety evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of multi-agent chemotherapy for pediatric ALL, Implement strategies to overcome barriers to the effective use of asparaginase in pediatric ALL, including the use of appropriate monitoring and management for hypersensitivity, mitigation for infusion reactions, and the integration of novel Erwinia asparaginase compounds into treatment plans.

Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.

Go online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings. Upon completion of this activity, participants should be better able to: Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting, Discuss evidence surrounding the efficacy and safety of novel therapeutics across the spectrum of CLL, including in higher-risk disease settings or in patients relapsing after multiple prior treatments, Recommend regimens with novel components for patients presenting with treatment-naïve, high-risk, or relapsed/refractory CLL.

Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

Go online to PeerView.com/AFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pharmacists have a central role in the management of chronic lymphocytic leukemia (CLL) and the delivery of potent targeted agents. How will new evidence influence the core tenets of pharmacy practice? In this activity, a leukemia clinical pharmacy specialist provides answers through a precise review of the newest targeted therapy standards for CLL. This program includes insights on the latest efficacy evidence and regulatory status of targeted agents in CLL, while addressing drug interactions, treatment adherence, safety considerations, dosing, and care coordination. Upon completion of this activity, participants should be better able to: Summarize the current treatment role, efficacy and safety evidence, and regulatory status of targeted therapy in CLL, including BTK, BCL-2, and PI3K inhibitors, Educate patients and clinical staff about potential drug–drug interactions, and appropriate dosing, safety, and drug delivery considerations related to the use of targeted agents for CLL, Apply team-based approaches to integrate novel therapies into customized CLL management while addressing drug interactions, adherence, safety, dosing, and care coordination.

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin's lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.

Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.

Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a recent live web broadcast, will provide essential updates and practical guidance regarding biomarker testing and individualized treatment of patients with HER2-altered cancers, and novel targets such as HER3 and TROP2 will be explored as well. Upon completion of this activity, participants should be better able to: Identify patients with solid tumors with HER2, HER3, and TROP2 alterations using established and emerging testing approaches, Incorporate therapies directed at HER2, HER3, and TROP2 into the treatment of patients with tumors with targetable alterations based on the characteristics, mechanisms of action, and latest clinical evidence on approved and emerging therapies, Develop individualized management plans that leverage predictive testing, the most recent clinical findings, and multidisciplinary team-based care in accordance with the latest treatment guidelines and recommendations for patients with solid tumors with HER2, HER3, and TROP2 alterations, either in the context of clinical practice or clinical trials.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.